PI Health Sciences Financial Overview

New products commercialisation driving growth in Exports and Q3FY24 revenues Pi Inspired by Science ☐ Fig in Rs. Million Q3FY23 Q3FY24 % YOY Overall 18% Y-o-Y revenue growth ☐ Revenue 16,132 18,975 18% Gross Margin 47% 54% 640 bps Overheads 3,456 4,626 34% EBITDA 4,156 5,550 34% EBITDA as % of 26% 29% 348 bps Revenue Net Profit 3,518 4,486 28% 23% -6% 34% 28% Mn Mn 16,310 5,550 13,286 4,156 4,486 ■ 3,518 ☐ ☐ 13% growth in Agchem Exports driven by volume growth and newly commercialised products. Pharma contributed Exports revenue of Rs. 1,273 million i.e. ~10% of total Exports revenue growth. Domestic revenues were subdued with reduction of ~6% Y-o-Y due to delayed and erratic spread of monsoon although favourable product mix and improved working capital management helped contain financial impact. Gross Margin and EBITDA improved mainly on account of favorable product mix, operating leverage and one-time impact of recovery of theft material contributing ~300 bps improvement in EBITDA. Overheads increase mainly attributable to the newly acquired Pharma businesses hence not comparable. The Board has considered interim dividend for FY23-24 of Rs 6.00 per share Exports Q3FY23 2,8462,665 Domestic Q3FY24 EBITDA Q3FY23 PAT Q3FY24 1 Pharma: Pl Health Sciences Ltd. ("PIHSL") Consolidated including overseas subsidiaries 4

View entire presentation